NASDAQ:AVGR - Avinger Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.4315 -0.02 (-4.43 %) (As of 02/22/2019 04:00 PM ET)Previous Close$0.4526Today's Range$0.4150 - $0.459852-Week Range$0.18 - $2.44Volume1.67 million shsAverage Volume2.50 million shsMarket Capitalization$10.12 millionP/E Ratio-0.01Dividend YieldN/ABeta1.65 ProfileDiscussionAnalyst RatingsChartEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Avinger, Inc., a commercial-stage medical device company, designs, manufactures, and sells image-guided and catheter-based systems used by physicians to treat patients with peripheral arterial disease (PAD) in the United States and Europe. It develops lumivascular platform that integrates optical coherence tomography visualization with interventional catheters to provide real-time intravascular imaging during the treatment portion of PAD procedures. The company's lumivascular products comprise Lightbox imaging consoles, as well as the Ocelot family of catheters, which are designed to penetrate a total blockage in an artery; and Pantheris, an image-guided atherectomy device that allows physicians to precisely remove arterial plaque in PAD patients. In addition, its first-generation chronic total occlusion (CTO)-crossing catheters, Wildcat, and Kittycat 2, which employs a proprietary design that uses a rotational spinning technique allowing the physician to switch between passive and active modes when navigating across a CTO. The company sells and markets its products to interventional cardiologists, vascular surgeons, and interventional radiologists. Avinger, Inc. was founded in 2007 and is headquartered in Redwood City, California. Receive AVGR News and Ratings via Email Sign-up to receive the latest news and ratings for AVGR and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Surgical & medical instruments Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AVGR Previous Symbol CUSIPN/A CIK1506928 Webwww.avinger.com Phone650-241-7900Debt Debt-to-Equity RatioN/A Current Ratio1.12 Quick Ratio0.87Price-To-Earnings Trailing P/E Ratio-0.01 Forward P/E Ratio-0.06 P/E GrowthN/A Sales & Book Value Annual Sales$9.93 million Price / Sales1.02 Cash FlowN/A Price / Cash FlowN/A Book Value($42.82) per share Price / Book-0.01Profitability EPS (Most Recent Fiscal Year)($70.07) Net Income$-48,730,000.00 Net Margins-416.08% Return on EquityN/A Return on Assets-158.54%Miscellaneous Employees65 Outstanding Shares23,458,000Market Cap$10.12 million Next Earnings Date3/18/2019 (Estimated) OptionableNot Optionable Avinger (NASDAQ:AVGR) Frequently Asked Questions What is Avinger's stock symbol? Avinger trades on the NASDAQ under the ticker symbol "AVGR." When did Avinger's stock split? How did Avinger's stock split work? Avinger's stock reverse split on the morning of Wednesday, January 31st 2018. The 1-40 reverse split was announced on Tuesday, January 30th 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, January 30th 2018. An investor that had 100 shares of Avinger stock prior to the reverse split would have 3 shares after the split. How were Avinger's earnings last quarter? Avinger Inc (NASDAQ:AVGR) released its quarterly earnings data on Tuesday, November, 13th. The medical device company reported ($0.56) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.51) by $0.05. The medical device company earned $2.02 million during the quarter. View Avinger's Earnings History. When is Avinger's next earnings date? Avinger is scheduled to release their next quarterly earnings announcement on Monday, March 18th 2019. View Earnings Estimates for Avinger. What is the consensus analysts' recommendation for Avinger? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avinger in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avinger. Has Avinger been receiving favorable news coverage? Headlines about AVGR stock have trended positive recently, InfoTrie Sentiment reports. The research firm scores the sentiment of media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Avinger earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave press coverage about the medical device company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the stock's share price in the near term. Who are some of Avinger's key competitors? Some companies that are related to Avinger include AIT Therapeutics (AITB), Nephros (NEPH), Restoration Robotics (HAIR), PAVmed (PAVM), Interpace Diagnostics Group (IDXG), SANUWAVE Health (SNWV), Lianluo Smart (LLIT), DarioHealth (DRIO), Neovasc (NVCN), Dynatronics (DYNT), Hancock Jaffe Laboratories (HJLI), Biostage (BSTG), Invivo Therapeutics (NVIV), Alliqua Biomedical (ALQA) and Valeritas (VLRX). What other stocks do shareholders of Avinger own? Based on aggregate information from My MarketBeat watchlists, some companies that other Avinger investors own include Check Cap (CHEK), Aralez Pharmaceuticals (ARLZ), Palatin Technologies (PTN), Micron Technology (MU), Neovasc (NVCN), Protalix Biotherapeutics (PLX), AVEO Pharmaceuticals (AVEO), CHF Solutions (CHFS), OncoSec Medical (ONCS) and Allena Pharmaceuticals (ALNA). Who are Avinger's key executives? Avinger's management team includes the folowing people: Mr. Jeffrey M. Soinski, Pres, CEO & Director (Age 57)Mr. Mark B. Weinswig, Chief Financial Officer (Age 46)Mr. Keith Schaefer, Chief Operating OfficerMr. Himanshu N. Patel, Chief Technology Officer (Age 59)Mr. Philip R. Preuss, VP of Marketing & Bus. Operations (Age 41) When did Avinger IPO? (AVGR) raised $60 million in an initial public offering (IPO) on Friday, January 30th 2015. The company issued 4,600,000 shares at a price of $12.00-$14.00 per share. Canaccord Genuity and Cowen and Company served as the underwriters for the IPO and Oppenheimer, BTIG and Stephens were co-managers. Who are Avinger's major shareholders? Avinger's stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (1.08%) and CVI Holdings LLC (0.63%). Company insiders that own Avinger stock include Himanshu Patel and John B Ph D Md Simpson. View Institutional Ownership Trends for Avinger. Which major investors are buying Avinger stock? AVGR stock was acquired by a variety of institutional investors in the last quarter, including Virtu Financial LLC and CVI Holdings LLC. View Insider Buying and Selling for Avinger. How do I buy shares of Avinger? Shares of AVGR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Avinger's stock price today? One share of AVGR stock can currently be purchased for approximately $0.4315. How big of a company is Avinger? Avinger has a market capitalization of $10.12 million and generates $9.93 million in revenue each year. The medical device company earns $-48,730,000.00 in net income (profit) each year or ($70.07) on an earnings per share basis. Avinger employs 65 workers across the globe. What is Avinger's official website? The official website for Avinger is http://www.avinger.com. How can I contact Avinger? Avinger's mailing address is 400 CHESAPEAKE DRIVE, REDWOOD CITY CA, 94063. The medical device company can be reached via phone at 650-241-7900 or via email at [email protected] MarketBeat Community Rating for Avinger (NASDAQ AVGR)Community Ranking: 2.7 out of 5 ( )Outperform Votes: 270 (Vote Outperform)Underperform Votes: 235 (Vote Underperform)Total Votes: 505MarketBeat's community ratings are surveys of what our community members think about Avinger and other stocks. Vote "Outperform" if you believe AVGR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AVGR will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 2/22/2019 by MarketBeat.com StaffFeatured Article: Can individual investors take part in an IPO?